Groupama Asset Managment Acquires 681 Shares of Stryker Co. (NYSE:SYK)

Groupama Asset Managment lifted its stake in shares of Stryker Co. (NYSE:SYK - Free Report) by 51.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,007 shares of the medical technology company's stock after acquiring an additional 681 shares during the period. Groupama Asset Managment's holdings in Stryker were worth $727,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Edgestream Partners L.P. lifted its holdings in shares of Stryker by 216.1% in the third quarter. Edgestream Partners L.P. now owns 3,430 shares of the medical technology company's stock valued at $1,239,000 after purchasing an additional 2,345 shares in the last quarter. Ascent Group LLC lifted its stake in Stryker by 2.0% in the 3rd quarter. Ascent Group LLC now owns 3,867 shares of the medical technology company's stock valued at $1,397,000 after acquiring an additional 77 shares in the last quarter. Hilltop Holdings Inc. boosted its position in Stryker by 161.2% during the 3rd quarter. Hilltop Holdings Inc. now owns 3,479 shares of the medical technology company's stock worth $1,257,000 after acquiring an additional 2,147 shares during the last quarter. Investment Management Corp of Ontario grew its stake in shares of Stryker by 26.0% during the 3rd quarter. Investment Management Corp of Ontario now owns 17,945 shares of the medical technology company's stock worth $6,483,000 after acquiring an additional 3,700 shares in the last quarter. Finally, Integrated Wealth Concepts LLC raised its holdings in shares of Stryker by 1.0% in the third quarter. Integrated Wealth Concepts LLC now owns 5,629 shares of the medical technology company's stock valued at $2,034,000 after purchasing an additional 54 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Insiders Place Their Bets

In related news, Director Ronda E. Stryker sold 201,392 shares of the company's stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the sale, the director now owns 3,642,075 shares of the company's stock, valued at $1,428,567,498. This represents a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Allan C. Golston sold 2,458 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the sale, the director now owns 14,895 shares in the company, valued at $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.50% of the company's stock.

Stryker Stock Performance

Shares of NYSE:SYK traded down $22.01 during trading on Friday, reaching $346.14. 3,956,734 shares of the stock were exchanged, compared to its average volume of 1,318,949. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19. The stock has a 50-day moving average price of $381.69 and a 200-day moving average price of $374.23. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The firm has a market cap of $132.12 billion, a PE ratio of 44.61, a PEG ratio of 2.93 and a beta of 0.95.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating analysts' consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period last year, the business posted $3.46 EPS. Research analysts expect that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 0.97%. The ex-dividend date is Monday, March 31st. Stryker's dividend payout ratio is currently 43.30%.

Analyst Ratings Changes

Several brokerages recently commented on SYK. JMP Securities restated a "market perform" rating on shares of Stryker in a report on Tuesday, February 18th. Citigroup restated a "buy" rating and issued a $450.00 price objective on shares of Stryker in a report on Wednesday, February 26th. JPMorgan Chase & Co. upped their target price on Stryker from $420.00 to $445.00 and gave the stock an "overweight" rating in a report on Wednesday, January 29th. Barclays increased their price target on Stryker from $418.00 to $443.00 and gave the company an "overweight" rating in a research report on Monday, February 10th. Finally, Argus set a $450.00 price objective on Stryker in a research note on Monday, February 3rd. Five research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $421.90.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.